PEIJIA-B (09996) announced its annual results for the period ending December 31, 2025. During the reporting period, the group achieved revenue of approximately RMB 7 billion to RMB 7.2 billion, representing a year-on-year increase of about 13.7% to 17.0%. The sustained revenue growth was primarily driven by strong performance across all three major product lines in the neurointerventional business, as well as the continued expansion of the company's market share in China's transcatheter aortic valve replacement (TAVR) market, largely due to the successful launch of the high-end TaurusMax® 3D adjustable TAVR system.

All three neurointerventional product lines recorded robust revenue growth, reflecting the solid performance of their respective core products. Key growth drivers included increased revenue from vascular access products, benefiting from the expanding sales volume of the high-performance DCwire® microguidewire, which led to rapid market share gains. The hemorrhagic product line saw revenue growth driven by the successful market introduction of the YonFlow® flow diverter stent. Ischemic product revenue growth was mainly attributed to increased sales of the Syphonet® thrombectomy stent and the Tethys AS® thrombus aspiration catheter.

Within the ischemic product portfolio, following the implementation of volume-based procurement in the second half of 2025, although the selling price of balloon dilatation catheters decreased, sales volume rose significantly—particularly for the Fastunnel® delivery balloon dilatation catheter—helping to maintain overall revenue stability compared to 2024.

During the reporting period, the group’s commercialized TAVR product portfolio—including the TaurusOne®, TaurusElite®, and TaurusMax® TAVR systems used nationwide to treat aortic valve stenosis, and the Trilogy™ transcatheter heart valve system used in Hong Kong and Taiwan for aortic regurgitation—was adopted in approximately 130 new hospitals. By December 31, 2025, the products had cumulatively covered more than 780 hospitals. A total of around 3,900 implantations were performed during the reporting period, representing a 14.4% year-on-year increase, significantly higher than the overall market growth rate.

With the registration application for the TaurusTrio® transcatheter aortic valve system approved by the National Medical Products Administration in December 2025, the company expects to begin full commercialization in China’s aortic regurgitation market.